Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence

Table 3 Subjective Improvement: Treatment Success Definition by Intervention

Study	Study Design	Sample Size	Study Population	Comparator	Success Evaluated (months)	Success %
Botulinum toxin type A
Loch, Eur Urol Supp, 2003* [60]	Open Label	30, 30	NOAB, IOAB	None	8, 8	67, 67
Rapp, Urology, 2004 [61]	Open Label	35	IOAB	None	6	60
Grosse, Eur Urol, 2005 [62]	Open Label	66	NOAB	None	10	86.3
Rajkumar, BJU Int, 2005 [63]	Open Label	15	IOAB	None	1.5	93
Schulte-Baukloh, Eur Urol, 2005 [64]	Open Label	44	IOAB	None	3	86
Schmid, J Urol, 2006 [65]	Open Label	100	IOAB	None	3	88
Schulte-Baukloh, Neur Urodyn, 2006 [66]	Open Label	16	NOAB	None	6	100
Kuo, J Urol, 2007 [67]	Open Label	45	IOAB	None	3	80
Augmentation cystoplasty
Edlund, Scand J Urol Nephrol, 2001 [68]	Open Label	25	IOAB	None	60	78
Barrington, Int Urogynecol J, 2006 [69]	Open Label	12	IOAB	None	12	83
Chartier-Kaslter, Spinal Cord, 2000 [43]	Open Label	17	NOAB	None	75.6	88.5
Quek, J Urol, 2003 [45]	Open Label	26	NOAB	None	96	96
Nomura, Spinal Cord, 2002 [70]	Open Label	11	NOAB	None	66	100

* Denotes a study with both neurogenic OAB (NOAB) and idiopathic OAB (IOAB) populations.
Note: Studies may be listed in more than one category of treatment success if multiple definitions of treatment success were reported.

ISSN: 1471-2490